Allergy Therapeutics Yönetim
Yönetim kriter kontrolleri 3/4
Allergy Therapeutics' CEO is Manuel Llobet, appointed in Jul 2009, has a tenure of 15.33 years. total yearly compensation is £411.98K, comprised of 83% salary and 17% bonuses, including company stock and options. directly owns 0.1% of the company’s shares, worth £275.08K. The average tenure of the management team and the board of directors is 8.9 years and 2.5 years respectively.
Anahtar bilgiler
Manuel Llobet
İcra Kurulu Başkanı
UK£412.0k
Toplam tazminat
CEO maaş yüzdesi | 83.0% |
CEO görev süresi | 15.3yrs |
CEO sahipliği | 0.1% |
Yönetim ortalama görev süresi | 8.9yrs |
Yönetim Kurulu ortalama görev süresi | 2.5yrs |
CEO Tazminat Analizi
Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
---|---|---|---|
Dec 31 2023 | n/a | n/a | -UK£50m |
Sep 30 2023 | n/a | n/a | -UK£47m |
Jun 30 2023 | UK£412k | UK£342k | -UK£43m |
Mar 31 2023 | n/a | n/a | -UK£36m |
Dec 31 2022 | n/a | n/a | -UK£29m |
Sep 30 2022 | n/a | n/a | -UK£21m |
Jun 30 2022 | UK£665k | UK£332k | -UK£14m |
Mar 31 2022 | n/a | n/a | -UK£10m |
Dec 31 2021 | n/a | n/a | -UK£5m |
Sep 30 2021 | n/a | n/a | -UK£1m |
Jun 30 2021 | UK£662k | UK£324k | UK£3m |
Mar 31 2021 | n/a | n/a | UK£5m |
Dec 31 2020 | n/a | n/a | UK£7m |
Sep 30 2020 | n/a | n/a | UK£7m |
Jun 30 2020 | UK£614k | UK£303k | UK£7m |
Mar 31 2020 | n/a | n/a | UK£8m |
Dec 31 2019 | n/a | n/a | UK£8m |
Sep 30 2019 | n/a | n/a | UK£6m |
Jun 30 2019 | UK£557k | UK£295k | UK£3m |
Mar 31 2019 | n/a | n/a | UK£117k |
Dec 31 2018 | n/a | n/a | -UK£3m |
Sep 30 2018 | n/a | n/a | -UK£5m |
Jun 30 2018 | UK£556k | UK£286k | -UK£8m |
Tazminat ve Piyasa: Manuel's total compensation ($USD534.65K) is below average for companies of similar size in the UK market ($USD1.01M).
Tazminat ve Kazançlar: Manuel's compensation has been consistent with company performance over the past year.
CEO
Manuel Llobet (59 yo)
15.3yrs
Görev süresi
UK£411,982
Tazminat
Mr. Manuel Llobet has been the Chief Executive Officer of Allergy Therapeutics plc since July 2009. Mr. Llobet joined Allergy in September 2009 following the successful refinancing by Azure Ventures Limite...
Liderlik Ekibi
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
CEO & Executive Director | 15.3yrs | UK£411.98k | 0.10% £ 275.1k | |
CFO & Executive Director | 1.3yrs | Veri yok | 0.000030% £ 78.6 | |
Group Operations Director | 8.9yrs | Veri yok | Veri yok | |
Chief Scientific Officer | 8.9yrs | Veri yok | Veri yok | |
Business Development Director | 15.1yrs | Veri yok | Veri yok | |
Head of Human Resources | no data | Veri yok | Veri yok | |
Head of Clinical Science | 7.2yrs | Veri yok | Veri yok | |
Head of Communication & Market Development | no data | Veri yok | Veri yok | |
Group Financial Controller | no data | Veri yok | Veri yok | |
Company Secretary | 1.8yrs | Veri yok | Veri yok | |
Principal Scientist | no data | Veri yok | Veri yok |
8.9yrs
Ortalama Görev Süresi
Deneyimli Yönetim: AGY's management team is seasoned and experienced (8.9 years average tenure).
Yönetim Kurulu Üyeleri
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
CEO & Executive Director | 15.3yrs | UK£411.98k | 0.10% £ 275.1k | |
CFO & Executive Director | less than a year | Veri yok | 0.000030% £ 78.6 | |
Senior Independent Director | 7.4yrs | UK£44.50k | 0.0010% £ 2.8k | |
Independent Chairman | 14.1yrs | UK£94.00k | 0.044% £ 115.5k | |
Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
Chairman of Scientific Advisory Board | no data | Veri yok | Veri yok | |
Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
Non-Executive Director | 1.9yrs | Veri yok | 0.040% £ 105.9k | |
Independent Non-Executive Director | 3.1yrs | UK£40.00k | Veri yok | |
Non-Executive Director | 1.9yrs | Veri yok | 0.0019% £ 5.0k | |
Independent Non-Executive Director | less than a year | Veri yok | Veri yok |
2.5yrs
Ortalama Görev Süresi
57.5yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: AGY's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.